within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD08_Solifenacin;

model Solifenacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 2.638888888888889e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.6,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00031666666666666665,
    Tlag = 0,
    Vdp = 0.756,
    k12 = 1.3055555555555555e-05,
    k21 = 1.3055555555555555e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Solifenacin</td></tr><tr><td>ATC code:</td><td>G04BD08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>600</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Solifenacin is an antimuscarinic medication used primarily for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and incontinence. It is an approved prescription drug and widely used in clinical practice to manage symptoms of urinary incontinence.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li><p>Tannenbaum, S, et al., &amp; Newgreen, D (2020). Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. <i>Pharmacology research &amp; perspectives</i> 8(6) e00684–None. DOI:<a href=\"https://doi.org/10.1002/prp2.684\">10.1002/prp2.684</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33231929/\">https://pubmed.ncbi.nlm.nih.gov/33231929</a></p></li><li><p>Taekema-Roelvink, ME, et al., &amp; Smulders, RA (2005). Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. <i>Clinical therapeutics</i> 27(9) 1403–1410. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2005.09.002\">10.1016/j.clinthera.2005.09.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16291413/\">https://pubmed.ncbi.nlm.nih.gov/16291413</a></p></li><li><p>Abrams, P, &amp; Andersson, KE (2007). Muscarinic receptor antagonists for overactive bladder. <i>BJU international</i> 100(5) 987–1006. DOI:<a href=\"https://doi.org/10.1111/j.1464-410X.2007.07205.x\">10.1111/j.1464-410X.2007.07205.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17922784/\">https://pubmed.ncbi.nlm.nih.gov/17922784</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G04BD08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Solifenacin;
